NSE: HIKAL | BSE: 524735

Falling Comet

Download real time

242.00 2.43 (1.01%)

47.02% Fall from 52W High

504.8K NSE+BSE Volume

NSE 23 Dec, 2025 3:31 PM (IST)

2,983.9

Market Cap

Above industry Median

Beta 1Year

Very Low volatility

Hikal Ltd. share price target and research reports

Name: Latest research reports of Hikal Ltd. authored by BP Wealth and published by - Trendlyne research reports.
Item: Hikal Ltd.
Rating: 1
Author: BP Wealth

Latest analyst research reports with target prices and PDF download for HIKAL, BSE:524735 Hikal Ltd.

Hikal Ltd.

29 Oct 2019

242.00

1.01%

BP Equities Hikal Ltd Q2FY20 Result Update

Sell: Hikal Ltd.

BP Wealth

custom duty) of INR154mn. The company posted revenues of INR 3,211mn with 18.7% YoY decline which was below our estimate of INR,4,845mn. Multiple factors affected revenue growth during the quarter such as 1) Crop protection business was affected by heavy flooding at Mahad facility in the month of august which led to temporary production shut down.2) Pharmaceutical business faced issue at taloja facility where MIDC had cut 50% of the water supply to all industries in that region during Q2 and destocking of some of the products by innovator clients led to postponement in product...

Hikal has lost -36.05% in the last 1 Year

Hikal Ltd.

29 Oct 2019

242.00

1.01%

Hikal Ltd

Buy: Hikal Ltd.

Target

ICICI Securities Limited

Hikal ventured into the pharma API business by virtue of acquisition of Novartis' Panoli plant in 2000. In a short span of time, banking on its chemistry skills, the company has been able to tap incremental customers via the CDMO route. Hikal also operates as a dedicated API supplier as it expands its portfolio. We expect the pharma segment to grow at a CAGR of...

Hikal has lost -32.67% in the last 6 Months

Hikal Ltd.

02 Aug 2019

242.00

1.01%

Hikal Ltd

Buy: Hikal Ltd.

Target

ICICI Securities Limited

Q1 revenues grew 23.8% YoY to | 403.2 crore (I-direct estimate: | 368.4 crore) on account of 15.2% YoY growth in pharma segment to | 203.9 crore (I-direct estimate: | 212.4 crore) and 34.1% YoY growth in crop protection segment to | 199.3 crore (I-direct estimate: | 156.1 crore). EBITDA margins contracted 163 bps YoY to 17.0%, (I-direct estimate: 18.5%), fall in gross margins (43.4% vs. 49.4% in Q1FY19) was partly offset by decline in other expenditure. EBITDA grew 13% YoY to | 68.5 crore (I-direct estimate: | 68.1 crore. Net profit grew 58.4% YoY to | 25.2 crore (I-direct estimate of | 18.5...

Hikal has lost -32.67% in the last 6 Months

Hikal Ltd.

13 May 2019

242.00

1.01%

BP Equities Hikal Ltd Q4FY19 Result Update

Buy: Hikal Ltd.

BP Wealth

in gross margin due to change in product mix, EBITDA margin manage to remain at 18.4% level, was 121bps lower than our estimate. Adj. PAT came above our estimate at INR333mn (est INR298mn) Sector Outlook supported by lower tax expense (30.8% vs 35.3%) and decline in interest cost....

Hikal has lost -36.05% in the last 1 Year

Hikal Ltd.

10 May 2019

242.00

1.01%

Hikal Ltd

Buy: Hikal Ltd.

Target

ICICI Securities Limited

Q4 revenues grew 17.2% YoY to | 457.5 crore (I-direct estimate: | 450.3 crore) on account of 20.7% YoY growth in the pharma segment to | 259.2 crore (I-direct estimate: | 268.4 crore) and 12.8% YoY growth in the crop protection segment to | 198.4 crore (I-direct estimate: | 175.8 crore). EBITDA margins remained at ~18.4%, (I-direct estimate: 19.2%). The fall in gross margins (75.8% vs. 79.3% in Q4FY18) was offset by a decline in employee cost and other expenditure. EBITDA grew 17.5% YoY to | 84 crore vis--vis I-direct estimate of | 86.6 crore. Net profit grew 31.6% YoY to | 33.3...

Number of FII/FPI investors decreased from 104 to 67 in Sep 2025 qtr

Hikal Ltd.

16 Apr 2019

242.00

1.01%

Hikal

Buy: Hikal Ltd.

Keynotes Financial Opiniery

One of very few global and only Indian company to provide Active Ingredients for both Pharmaceuticals Agrochemical Hybrid Model....

Hikal has lost -32.67% in the last 6 Months

Hikal Ltd.

19 Mar 2019

242.00

1.01%

Hikal Ltd

Buy: Hikal Ltd.

Target

ICICI Securities Limited

Hikal ventured into the pharma API business by virtue of acquisition of Novartis' Panoli plant in the year 2000. In a short span of time, banking on its chemistry skills, the company has been able to tap incremental customers via the CDMO route. Hikal also operates as a dedicated API supplier as it expands its portfolio. We expect the pharma segment to grow at a CAGR of...

Number of FII/FPI investors decreased from 104 to 67 in Sep 2025 qtr

Hikal Ltd.

12 Oct 2018

242.00

1.01%

Hikal Ltd

Buy: Hikal Ltd.

ICICI Securities Limited

Hikal has lost -32.67% in the last 6 Months

Hikal Ltd.

19 Sep 2018

242.00

1.01%

Hikal Ltd

Not Rated: Hikal Ltd.

ICICI Securities Limited

We met the management of Hikal Ltd (Hikal) to gain an insight into the company's pharma and agrochem businesses. Established in 1988, Hikal is a B2B player, which provides active ingredients, intermediates and R&D; services to global pharmaceuticals, animal health, crop protection and specialty chemicals companies. For FY18, pharma and agrochem accounted for 58% and 42%, respectively, of total operating revenues. The pharma business is currently divided almost equally between generic active pharma ingredients (APIs) and contract research and...

Hikal Ltd. is trading above its 50 day SMA of 237.2

Hikal Ltd.

21 Mar 2018

242.00

1.01%

HIKAL LTD

Buy: Hikal Ltd.

Choice India

Valuation: At CMP of Rs. 208 ,Hikal Ltd. is trading at a P/E multiple of 21.6(x) compared to the industry peer of 36.5(x). The company has an upside potential of 20% to 25% in the next 12 to 18 months. We arrive at a target price in range of...

Number of FII/FPI investors decreased from 104 to 67 in Sep 2025 qtr

Is Hikal Ltd. worth buying?

258 Votes:

Buy 79.07%

Sell 12.79%

Hold 8.14%